Covidien is a $12 billion global healthcare products leader dedicated to innovation and long-term growth. Covidien creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more.
CSL Behring is a global manufacturer of coagulation factor concentrates for management of rare congenital coagulation deficiencies like hemophilia or FXIII deficiency, immune deficiencies, anticoagulant reversal and management of perioperative bleeding.
ETView and its VivaSight portfolio provide the surgical team with next-generation airway management products required for a range of lung isolation procedures.
VivaSight™-SL (Single-Lumen tube) and VivaSight™-DL (Double-Lumen tube) are fully integrated imaging/ ventilation systems available to the anesthesiologist that allow continuous airway visualization and ventilation for accurate placement and constant airway control. Using VivaSight does not require any modifications to the standard intubation procedure.
Contact: Mr. Ohad Lavi, VP Sales
Tel: +972 54 2854441
Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma derivatives (i.e. albumin), hospital pharmacy products and diagnostic technology for clinical use.
As a leading global producer of plasma derivatives, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain and employs more than 11,000 people worldwide.
Hamamatsu Photonics is a world leader in the manufacture of opto-electronic devices, including many for the medical market. The new NIRO-200NX Monitor enables the monitoring of the cerebral or systemic oxygenation. Any effects caused by drug, ventilation and patient management on the local haemodynamics can be detected by the NIRO-200NX and it is routinely used in hospitals.
Philips is one of the world's leading healthcare technology companies. We are committed to understanding the technological and human needs of patients and caregivers and to delivering solutions that enable more confident diagnoses, more efficient delivery of care, and more positive user experiences. People focused. Healthcare simplified: www.philips.com/healthcare
A global biopharmaceutical company focused on advancing treatment of critical care patients through delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. We have the marketed products Angiox® (bivalirudin), approved by the European Medicines Agency and therefore available in Spain (www.angiox.com), Cleviprex® (clevidipine) injectable emulsion which is marketed in the U.S.; Cleviprex® 0.5 mg/ml emulsion for injection (clevidipine) is approved but not available in Spain*; and Recothrom® Recombinant thrombin, which is marketed in the U.S. and is not approved in Spain.* We have a pipeline of critical care hospital products in development, including latestage development product candidates; and early stage development projects. In addition, the Company has marketing rights in the U.S. and Canada (not in Spain*) to a ready-to-use formulation of Argatroban and an injectable generic portfolio.
|The Medicines Company|
* no autorizado y/o no comercializado en España